J A Wall1, S Meza-Perez2, C B Scalise1, A Katre1, A I Londoño1, W J Turbitt3, T Randall2, L A Norian4, R C Arend5. 1. Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. 2. Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. 3. Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA. 4. Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA. 5. Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address: rarend@uabmc.edu.
Abstract
OBJECTIVE: Immune checkpoint blockade (ICB) therapy shows limited efficacy in ovarian cancers due to the "cold" immune phenotype surrounding these tumors. Previous studies have shown that in ovarian cancer Wnt/β-catenin pathway activation contributes to this immune phenotype. Here, we evaluated the anti-tumor and immune-enhancing properties of the Wnt inhibitor, CGX-1321, used alone or in combination with either DKN-01 or anti-PD-1 therapy, in pre-clinical ovarian cancer models. METHODS: The parental ID8 murine ovarian cancer model harboring a knock-out of p53 (ID8p53-/-) and MISIIR-Tag spontaneous ovarian cancer models were used to test the effects of CGX-1321 alone or in combination therapies on tumor burden and immune cell landscape in the tumor microenvironment (TME). Flow cytometry and NanoString analyses were used to characterize the changes in tumor-intrinsic signaling and immune-related profiles in the TME of ovarian cancer in response to treatments. RESULTS: CGX-1321 significantly reduced tumor burden and constrained tumor progression in the ID8p53-/- and MISIIR-Tag models. Furthermore, CGX-1321 increased infiltrating CD8+ T cells in the TME. Combining CGX-1321 with either DKN-01 or anti-PD-1 therapy also decreased tumor burden and increased CD8+ T cell infiltration in the omentum TME but did not do so to a greater extent that CGX-1321 monotherapy. CONCLUSIONS: CGX-1321 significantly reduced tumor burden and enhanced CD8+ T cell levels in ovarian cancer, nevertheless the addition of DKN-01 or anti-PD-1 therapies did not enhance these effects of CGX-1321. Further investigation is needed to determine if CGX-1321 + DKN-01 combination treatment sensitizes pre-clinical ovarian cancer to ICB therapy.
OBJECTIVE: Immune checkpoint blockade (ICB) therapy shows limited efficacy in ovarian cancers due to the "cold" immune phenotype surrounding these tumors. Previous studies have shown that in ovarian cancer Wnt/β-catenin pathway activation contributes to this immune phenotype. Here, we evaluated the anti-tumor and immune-enhancing properties of the Wnt inhibitor, CGX-1321, used alone or in combination with either DKN-01 or anti-PD-1 therapy, in pre-clinical ovarian cancer models. METHODS: The parental ID8 murine ovarian cancer model harboring a knock-out of p53 (ID8p53-/-) and MISIIR-Tag spontaneous ovarian cancer models were used to test the effects of CGX-1321 alone or in combination therapies on tumor burden and immune cell landscape in the tumor microenvironment (TME). Flow cytometry and NanoString analyses were used to characterize the changes in tumor-intrinsic signaling and immune-related profiles in the TME of ovarian cancer in response to treatments. RESULTS: CGX-1321 significantly reduced tumor burden and constrained tumor progression in the ID8p53-/- and MISIIR-Tag models. Furthermore, CGX-1321 increased infiltrating CD8+ T cells in the TME. Combining CGX-1321 with either DKN-01 or anti-PD-1 therapy also decreased tumor burden and increased CD8+ T cell infiltration in the omentum TME but did not do so to a greater extent that CGX-1321 monotherapy. CONCLUSIONS: CGX-1321 significantly reduced tumor burden and enhanced CD8+ T cell levels in ovarian cancer, nevertheless the addition of DKN-01 or anti-PD-1 therapies did not enhance these effects of CGX-1321. Further investigation is needed to determine if CGX-1321 + DKN-01 combination treatment sensitizes pre-clinical ovarian cancer to ICB therapy.
Authors: Denise C Connolly; Rudi Bao; Alexander Yu Nikitin; Kasie C Stephens; Timothy W Poole; Xiang Hua; Skye S Harris; Barbara C Vanderhyden; Thomas C Hamilton Journal: Cancer Res Date: 2003-03-15 Impact factor: 12.701
Authors: Jake S O'Donnell; Georgina V Long; Richard A Scolyer; Michele W L Teng; Mark J Smyth Journal: Cancer Treat Rev Date: 2016-11-27 Impact factor: 12.111
Authors: Aude-Hélène Capietto; Seokho Kim; Dominic E Sanford; David C Linehan; Masaki Hikida; Tomohiro Kumosaki; Deborah V Novack; Roberta Faccio Journal: J Exp Med Date: 2013-10-14 Impact factor: 14.307
Authors: Lucia D'Amico; Sahil Mahajan; Aude-Hélène Capietto; Zhengfeng Yang; Ali Zamani; Biancamaria Ricci; David B Bumpass; Melissa Meyer; Xinming Su; Andrea Wang-Gillam; Katherine Weilbaecher; Sheila A Stewart; David G DeNardo; Roberta Faccio Journal: J Exp Med Date: 2016-04-04 Impact factor: 14.307
Authors: Dimitrios N Sidiropoulos; Christine I Rafie; Julie K Jang; Sofi Castanon; Aaron G Baugh; Edgar Gonzalez; Brian J Christmas; Valerie H Narumi; Emily F Davis-Marcisak; Gaurav Sharma; Emma Bigelow; Ajay Vaghasia; Anuj Gupta; Alyza Skaist; Michael Considine; Sarah J Wheelan; Sathish Kumar Ganesan; Min Yu; Srinivasan Yegnasubramanian; Vered Stearns; Roisin M Connolly; Daria A Gaykalova; Luciane T Kagohara; Elizabeth M Jaffee; Elana J Fertig; Evanthia T Roussos Torres Journal: Cancer Immunol Res Date: 2022-05-03 Impact factor: 12.020
Authors: Rebecca C Arend; Carly B Scalise; Emily R Gordon; Allison M Davis; McKenzie E Foxall; Bobbi E Johnston; David K Crossman; Sara J Cooper Journal: Clin Cancer Res Date: 2022-04-01 Impact factor: 13.801